TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Aerobic High Intensity Training on Symptoms, Cognition, Cortical Structure, Substance Use and Metabolic Indices in Patients With Schizophrenia Spectrum Disorder
Brief Summary: Physical health problems are common in schizophrenia with a two- to three-fold increased morbidity and mortality rate, resulting in a 20 years reduction in life expectancy. A genetic vulnerability for developing cardiovascular disease has been documented in these patients, and many lifestyle factors also negatively influence physical health. Patients with schizophrenia are likely to smoke, are physically inactive and overweight, suffer from malnutrition due to unhealthy diet, and have reduced cardiorespiratory fitness. Moreover, these patients have increased risk of developing diabetes mellitus type II and metabolic syndrome. These aspects demonstrate the need for multi-disciplinary treatments of patients with schizophrenia and underline the need for addressing their physical health.

Poor physical fitness seems to be associated with exacerbated negative symptoms and increased cognitive dysfunction in patients with schizophrenia. However, evidence on physical activity and its consequences in schizophrenia is scarce. In this randomized controlled trial we investigate the effects of high intensity training in outpatients with schizophrenia on psychotic symptoms and well-being, cognition and cortical structure, tobacco smoking and substance use, in addition to metabolic indices.


Options:
A: Arm Label: Physical activity; Type: EXPERIMENTAL; Interventions: Other: Physical activity | Arm Label: Computer game skills training; Type: ACTIVE_COMPARATOR; Interventions: Other: Computer game skills training | Intervention Type: OTHER; Name: Computer game skills training; Assigned to Arm(s): Computer game skills training | Intervention Type: OTHER; Name: Physical activity; Assigned to Arm(s): Physical activity
B: Arm Label: Posit Science; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Remediation | Arm Label: Nintendo Brain Age; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nintendo Brain Age | Intervention Type: BEHAVIORAL; Name: Cognitive Remediation; Assigned to Arm(s): Posit Science | Intervention Type: BEHAVIORAL; Name: Nintendo Brain Age; Assigned to Arm(s): Nintendo Brain Age
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer games | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Neuroadaptive cognitive training | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Neuroadaptive cognitive training | Intervention Type: BEHAVIORAL; Name: Neuroadaptive cognitive training; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Computer games; Assigned to Arm(s): 1
D: Arm Label: Cognitive Remediation; Type: EXPERIMENTAL; Interventions: Drug: Cognitive Remediation | Arm Label: Cognitive activity control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Cognitive Remediation; Assigned to Arm(s): Cognitive Remediation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial of the Ketogenic Diet in the Treatment of Epilepsy in Children Under the Age of Two Years
Brief Summary: Epilepsy, a condition where individuals are prone to recurrent epileptic seizures, is the most common chronic neurological disorder in children. Epilepsy onset is most common in the first two years of life and is associated with poor prognosis for seizure control and neurodevelopmental outcome.

The ketogenic diet (KD) is a medically supervised diet that is high in fat and restricted in carbohydrates and protein. KD therapy has shown to be an effective treatment for seizures in children with epilepsy older than two. Associated benefits include: a reduced requirement for routine and emergency antiepileptic drugs (AED) and fewer seizure related hospital admissions. Although reports suggest that KD therapy improves seizures in younger children there is no high quality trial data that demonstrates effectiveness and safety in this age group. The KD is resource intensive, requiring dietetic and physician time; data is required to justify expansion of services to cater for the apparent need.

The investigators therefore propose a prospective multicentre randomised trial to investigate the effectiveness and safety of the KD in children with epilepsy under the age of 2, who have failed to respond to two or more AEDs. Children will be randomly assigned to either receive the KD or further AEDs. The allocated treatment will be started after a 2week baseline period, and it's effectiveness assessed after 8 weeks. Seizure diaries will be used to record seizures and related events, a questionnaire will be used to assess diet tolerance; also growth and blood biochemistry will be monitored.

The information obtained from this study is necessary to optimise choices in epilepsy treatment, aiming to improve outcomes and thus determine whether and when the KD should should be used.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: Ketogenic diet; Assigned to Arm(s): N/A
B: Arm Label: Atkins diet group; Type: N/A; Interventions: N/A | Arm Label: Ketogenic diet group; Type: N/A; Interventions: N/A
C: Arm Label: Ketogenic diet; Type: EXPERIMENTAL; Interventions: Other: Ketogenic diet | Arm Label: Antiepileptic drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiepileptic drug therapy | Intervention Type: OTHER; Name: Ketogenic diet; Assigned to Arm(s): Ketogenic diet | Intervention Type: DRUG; Name: Antiepileptic drug therapy; Assigned to Arm(s): Antiepileptic drug therapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Modified Atkins diet | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Modified Atkins diet; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Clinical Trial of Myopia Control in Schoolchildren Using the Multi-segment (MS) Lens
Brief Summary: The purpose of this study is to determine if the Multiple-Segment (MS) spectacle lens can slow myopia progression in Hong Kong schoolchildren.

MS lens is also called Defocus Incorporated Multiple Segments (DIMS) spectacle lens


Options:
A: Arm Label: ortho-k and 0.01% atropine eye drops; Type: EXPERIMENTAL; Interventions: Drug: 0.01% atropine eye drops, Device: ortho-k | Arm Label: ortho-k; Type: ACTIVE_COMPARATOR; Interventions: Device: ortho-k | Intervention Type: DRUG; Name: 0.01% atropine eye drops; Assigned to Arm(s): ortho-k and 0.01% atropine eye drops | Intervention Type: DEVICE; Name: ortho-k; Assigned to Arm(s): ortho-k, ortho-k and 0.01% atropine eye drops
B: Arm Label: Contact Lens; Type: EXPERIMENTAL; Interventions: Device: Soft contact lenses | Arm Label: Spectacle; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacle | Intervention Type: DEVICE; Name: Soft contact lenses; Assigned to Arm(s): Contact Lens | Intervention Type: DEVICE; Name: Spectacle; Assigned to Arm(s): Spectacle
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Ready-made spectacles | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacles | Intervention Type: DEVICE; Name: Ready-made spectacles; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Spectacles; Assigned to Arm(s): 2
D: Arm Label: Single vision spectacle lens; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Multiple-Segment spectacle lens; Type: EXPERIMENTAL; Interventions: Device: Multiple-Segment spectacle lens | Intervention Type: DEVICE; Name: Multiple-Segment spectacle lens; Assigned to Arm(s): Multiple-Segment spectacle lens

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Telehealth Intervention to Promote Chronic Disease Management After Stroke: A Pilot Randomized Controlled Study
Brief Summary: The purpose of this study is to examine the efficacy of a lifestyle modification telehealth program on health-related behaviours in community-dwelling individuals living with stroke.


Options:
A: Arm Label: Memory Training Program; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Healthy Lifestyle Training Program; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Lifestyle Training Program | Intervention Type: BEHAVIORAL; Name: Healthy Lifestyle Training Program; Assigned to Arm(s): Healthy Lifestyle Training Program
B: Arm Label: Regular care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Support program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient centered structured support program | Intervention Type: BEHAVIORAL; Name: Patient centered structured support program; Assigned to Arm(s): Support program
C: Arm Label: Standard care (SC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Interventional care (IC); Type: EXPERIMENTAL; Interventions: Behavioral: CAPSYS | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard care (SC) | Intervention Type: BEHAVIORAL; Name: CAPSYS; Assigned to Arm(s): Interventional care (IC)
D: Arm Label: 1: Care management; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management | Arm Label: 2: Written Materials; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written Materials | Intervention Type: BEHAVIORAL; Name: Care Management; Assigned to Arm(s): 1: Care management | Intervention Type: BEHAVIORAL; Name: Written Materials; Assigned to Arm(s): 2: Written Materials

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Telehealth Intervention to Promote Chronic Disease Management After Stroke: A Pilot Randomized Controlled Study
Brief Summary: The purpose of this study is to examine the efficacy of a lifestyle modification telehealth program on health-related behaviours in community-dwelling individuals living with stroke.


Options:
A: Arm Label: Feedback group; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of daily walking activity | Arm Label: No-feedback group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Feedback of daily walking activity; Assigned to Arm(s): Feedback group
B: Arm Label: Control Group; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Programme Only Group; Type: EXPERIMENTAL; Interventions: Device: Fitbit, Other: Usual Care | Arm Label: Cash Incentive Group; Type: EXPERIMENTAL; Interventions: Device: Fitbit, Behavioral: Cash Incentives, Other: Usual Care | Arm Label: Charitable Incentive Group; Type: EXPERIMENTAL; Interventions: Device: Fitbit, Behavioral: Charitable Incentives, Other: Usual Care | Intervention Type: DEVICE; Name: Fitbit; Assigned to Arm(s): Cash Incentive Group, Charitable Incentive Group, Programme Only Group | Intervention Type: BEHAVIORAL; Name: Cash Incentives; Assigned to Arm(s): Cash Incentive Group | Intervention Type: BEHAVIORAL; Name: Charitable Incentives; Assigned to Arm(s): Charitable Incentive Group | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Cash Incentive Group, Charitable Incentive Group, Control Group, Programme Only Group
C: Arm Label: Memory Training Program; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Healthy Lifestyle Training Program; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Lifestyle Training Program | Intervention Type: BEHAVIORAL; Name: Healthy Lifestyle Training Program; Assigned to Arm(s): Healthy Lifestyle Training Program
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Tele-Rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Tele-rehabilitation | Intervention Type: OTHER; Name: Tele-rehabilitation; Assigned to Arm(s): Tele-Rehabilitation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Telehealth Intervention to Promote Chronic Disease Management After Stroke: A Pilot Randomized Controlled Study
Brief Summary: The purpose of this study is to examine the efficacy of a lifestyle modification telehealth program on health-related behaviours in community-dwelling individuals living with stroke.


Options:
A: Arm Label: Memory Training Program; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Healthy Lifestyle Training Program; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Lifestyle Training Program | Intervention Type: BEHAVIORAL; Name: Healthy Lifestyle Training Program; Assigned to Arm(s): Healthy Lifestyle Training Program
B: Arm Label: 1: Care management; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management | Arm Label: 2: Written Materials; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written Materials | Intervention Type: BEHAVIORAL; Name: Care Management; Assigned to Arm(s): 1: Care management | Intervention Type: BEHAVIORAL; Name: Written Materials; Assigned to Arm(s): 2: Written Materials
C: Arm Label: PREVENT program; Type: EXPERIMENTAL; Interventions: Behavioral: PREVENT program | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: PREVENT program; Assigned to Arm(s): PREVENT program | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Intervention for diet, exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational intervention for diet and physical activity | Arm Label: Control; Type: OTHER; Interventions: Behavioral: Educational message on skin cancer awareness | Intervention Type: BEHAVIORAL; Name: Educational intervention for diet and physical activity; Assigned to Arm(s): Intervention for diet, exercise | Intervention Type: BEHAVIORAL; Name: Educational message on skin cancer awareness; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Social Media Intervention for Young Adult Smokers
Brief Summary: This randomized clinical trial will test the efficacy of a Facebook intervention based on the Transtheoretical Model (Prochaska and DiClemente) and US Public Health Service Clinical Practice Guidelines with young adults who smoke cigarettes who are age 18 to 25 (N=480).


Options:
A: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
B: Arm Label: San Francisco Internet Stop Smoking Site; Type: EXPERIMENTAL; Interventions: Behavioral: UCSF/SFGH Internet Stop Smoking Study site | Intervention Type: BEHAVIORAL; Name: UCSF/SFGH Internet Stop Smoking Study site; Assigned to Arm(s): San Francisco Internet Stop Smoking Site
C: Arm Label: Facebook intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook intervention | Arm Label: Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smokefree.gov | Intervention Type: BEHAVIORAL; Name: Facebook intervention; Assigned to Arm(s): Facebook intervention | Intervention Type: BEHAVIORAL; Name: Smokefree.gov; Assigned to Arm(s): Referral
D: Arm Label: Basic Internet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Internet | Arm Label: Enhanced Internet; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Internet | Arm Label: Enhanced Internet plus Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Internet + phone | Intervention Type: BEHAVIORAL; Name: Basic Internet; Assigned to Arm(s): Basic Internet | Intervention Type: BEHAVIORAL; Name: Enhanced Internet; Assigned to Arm(s): Enhanced Internet | Intervention Type: BEHAVIORAL; Name: Enhanced Internet + phone; Assigned to Arm(s): Enhanced Internet plus Phone

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Social Media Intervention for Young Adult Smokers
Brief Summary: This randomized clinical trial will test the efficacy of a Facebook intervention based on the Transtheoretical Model (Prochaska and DiClemente) and US Public Health Service Clinical Practice Guidelines with young adults who smoke cigarettes who are age 18 to 25 (N=480).


Options:
A: Arm Label: Text Messaging; Type: EXPERIMENTAL; Interventions: Behavioral: text messaging for smoking cessation | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic text messages | Intervention Type: BEHAVIORAL; Name: text messaging for smoking cessation; Assigned to Arm(s): Text Messaging | Intervention Type: BEHAVIORAL; Name: Generic text messages; Assigned to Arm(s): Control
B: Arm Label: Control group; Type: OTHER; Interventions: Other: Control group | Arm Label: Cell phone Aplication for Smarth Phone; Type: ACTIVE_COMPARATOR; Interventions: Device: Cell phone Aplication for Smarth Phone | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group | Intervention Type: DEVICE; Name: Cell phone Aplication for Smarth Phone; Assigned to Arm(s): Cell phone Aplication for Smarth Phone
C: Arm Label: Experimental App; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental App | Arm Label: Active comparator app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Comparator App | Intervention Type: BEHAVIORAL; Name: Experimental App; Assigned to Arm(s): Experimental App | Intervention Type: BEHAVIORAL; Name: Active Comparator App; Assigned to Arm(s): Active comparator app
D: Arm Label: Facebook intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook intervention | Arm Label: Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smokefree.gov | Intervention Type: BEHAVIORAL; Name: Facebook intervention; Assigned to Arm(s): Facebook intervention | Intervention Type: BEHAVIORAL; Name: Smokefree.gov; Assigned to Arm(s): Referral

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
Brief Summary: The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.


Options:
A: Arm Label: Group I; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group II; Type: PLACEBO_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group III; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Adalimumab | Intervention Type: DRUG; Name: Guselkumab 100 mg; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Placebo for guselkumab; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Group III | Intervention Type: DRUG; Name: Placebo for adalimumab; Assigned to Arm(s): Group I, Group II
B: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Etanercept + Acitretin | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Etanercept + Acitretin; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Group C
D: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment
Brief Summary: The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash).


Options:
A: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Fumaric Acid Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaric Acid Esters, Drug: Ixekizumab | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Ixekizumab | Intervention Type: DRUG; Name: Fumaric Acid Esters; Assigned to Arm(s): Fumaric Acid Esters | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Fumaric Acid Esters, Ixekizumab, Methotrexate
B: Arm Label: PF-06700841 Oral Solution/Suspension; Type: EXPERIMENTAL; Interventions: Drug: PF-06700841 oral solution/suspension | Arm Label: PF-06700841 Tablet; Type: EXPERIMENTAL; Interventions: Drug: PF-06700841 tablet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: PF-06700841 oral solution/suspension; Assigned to Arm(s): PF-06700841 Oral Solution/Suspension | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: PF-06700841 tablet; Assigned to Arm(s): PF-06700841 Tablet
C: Arm Label: Group I; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group II; Type: PLACEBO_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group III; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Adalimumab | Intervention Type: DRUG; Name: Guselkumab 100 mg; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Placebo for guselkumab; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Group III | Intervention Type: DRUG; Name: Placebo for adalimumab; Assigned to Arm(s): Group I, Group II
D: Arm Label: 80 mg Ixekizumab Auto-Injector; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Auto-Injector | Arm Label: 80 mg Ixekizumab Prefilled Syringe; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Prefilled Syringe | Intervention Type: DRUG; Name: Ixekizumab Auto-Injector; Assigned to Arm(s): 80 mg Ixekizumab Auto-Injector | Intervention Type: DRUG; Name: Ixekizumab Prefilled Syringe; Assigned to Arm(s): 80 mg Ixekizumab Prefilled Syringe

Answer: C